06:23 AM EDT, 09/15/2026 (MT Newswires) -- Proteome Sciences (PRM.L) confirmed it has secured the significant clinical contract for its chemoproteomics platform, initially announced in June. The contract proteomics services company expected the contract to serve as a precursor to a new clinical trial program in 2026, which it will carry out at its laboratories in Frankfurt, Germany, in line with Good Clinical Laboratory Practice accreditation. Proteome Sciences expects the majority of the work in the contract to be completed in 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.